PerspectiveCancer Drug Discovery

Targeting a Common Collaborator in Cancer Development

See allHide authors and affiliations

Science Translational Medicine  08 Sep 2010:
Vol. 2, Issue 48, pp. 48ps45
DOI: 10.1126/scitranslmed.3001251

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


In this issue of Science Translational Medicine, Wallin et al. have identified a subset of breast and ovarian cancer cell lines that show synergistic response to the combination of doxorubicin and GDC-0941, a class IA phosphatidylinositol 3-kinase (PI3K) inhibitor. Here, we discuss the potential implications of these data on the clinical development of PI3K pathway inhibitors as cancer therapeutics.


  • Citation: A. P. Myers, L. C. Cantley, Targeting a common collaborator in cancer development. Sci. Transl. Med. 2, 48ps45 (2010).

View Full Text

Stay Connected to Science Translational Medicine